Nuvalent, Inc.NUVLNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

prnewswire.com

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026

CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new data for zidesamtinib, an investigational ROS1-selective inhibitor, during two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22 in San Diego.

defenseworld.net

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of “Moderate Buy” by Analysts

Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the sixteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and fifteen have assigned a buy recommendation to the company. The average 12 month price

fool.com

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

Vestal Point Capital sold 1,054,000 Nuvalent shares in the fourth quarter, an estimated $103.93 million trade based on quarterly average pricing. The fund's quarter-end Nuvalent position value declined by $90.50 million, reflecting both trading activity and stock price movement.

defenseworld.net

Nuvalent, Inc. $NUVL Shares Sold by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC cut its stake in Nuvalent, Inc. (NASDAQ: NUVL) by 2.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 362,585 shares of the company's stock after selling 7,273 shares during the period. ArrowMark Colorado Holdings

zacks.com

Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in Nuvalent (NUVL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

prnewswire.com

Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results

Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential label expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026 Strong financial position with operating runway anticipated into 2029 CAMBRIDGE, Mass., Feb. 26, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline progress, reiterated key anticipated milestones, and reported fourth quarter and full year 2025 financial results.

fool.com

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

Commodore Capital reduced its Nuvalent stake by 850,000 shares in the fourth quarter; the estimated trade size was $83.81 million based on quarterly average pricing. Meanwhile, the quarter-end position value dropped by $65.75 million, reflecting both share sales and stock price movement.

defenseworld.net

Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans

Nuvalent (NASDAQ: NUVL) executives highlighted ongoing regulatory milestones for the company's lead oncology programs and discussed commercialization strategy, pipeline plans, and financial positioning during a conference fireside chat. Company focus and lead programs Chief Executive Officer Jim Porter described Nuvalent as a company built around deep chemistry and structure-based drug design expertise, with an emphasis on

prnewswire.com

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

defenseworld.net

Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) have earned an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating on the company. The average 12-month

247wallst.com

3 Biotech Stocks That Could Double In 2026

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).

seekingalpha.com

Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

prnewswire.com

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026 Well capitalized with operating runway anticipated into 2029 Company to present at 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th at 9:00 a.m.

defenseworld.net

Nuvalent (NASDAQ:NUVL) CFO Sells $412,247.52 in Stock

Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CFO Alexandra Balcom sold 4,236 shares of Nuvalent stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the sale, the chief financial officer directly owned 84,914 shares of the company's stock, valued

defenseworld.net

Nuvalent (NASDAQ:NUVL) Insider Sells $424,607.16 in Stock

Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) insider Deborah Ann Miller sold 4,363 shares of Nuvalent stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total value of $424,607.16. Following the completion of the transaction, the insider directly owned 44,723 shares of the company's

defenseworld.net

Nuvalent (NASDAQ:NUVL) Insider Sells $412,247.52 in Stock

Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) insider Christopher Durant Turner sold 4,236 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the transaction, the insider owned 58,311 shares of the company's stock, valued

defenseworld.net

James Richard Porter Sells 17,890 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CEO James Richard Porter sold 17,890 shares of Nuvalent stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $97.32, for a total transaction of $1,741,054.80. Following the transaction, the chief executive officer directly owned 288,172 shares of the company's stock,

feeds.benzinga.com

What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.

zacks.com

3 Biotech Stocks With Major 2026 Catalysts

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.

prnewswire.com

Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance